Centre Hospitalier Du Puy
- Address
- lock Available on a paid plan
Kidney and Cardiovascular Research
At Centre Hospitalier Du Puy, clinical research in nephrology and cardiovascular diseases focuses on conditions such as immunoglobulin A nephropathy, chronic kidney disease, acute kidney injury, and broader heart and blood vessel disease. These studies are designed to test new treatment options, slow kidney function loss, and reduce major cardiovascular events in people at elevated risk.
- Immunoglobulin A nephropathy and proteinuria reduction
- Chronic kidney disease with high blood pressure and cardiovascular risk
- Acute kidney injury recovery and long-term outcomes
- Cardiovascular disease prevention in advanced kidney disease
Much of this work explores whether newer therapies can better protect kidney function while also improving overall cardiovascular health.
Autoimmune and Inflammatory Diseases
The site also supports trials in immune system diseases, especially rheumatoid arthritis. Research here is aimed at finding more effective ways to control persistent inflammation and improve symptoms in patients whose disease has not responded well to standard care.
- Rheumatoid arthritis with refractory disease
- Immune system processes involved in treatment response
- Combination treatment strategies for better disease control
These studies help clarify whether newer immune-targeted approaches can offer stronger and more lasting relief.
Oncology and Cancer Care
Clinical trials in neoplasms at this hospital include research in breast cancer, colon carcinoma, and follicular lymphoma. The main goals are to improve treatment effectiveness, refine cancer management after diagnosis, and support better outcomes for patients with advanced or recurrent disease.
- Estrogen receptor-positive, HER2-negative breast cancer
- Colon cancer and tumor DNA-guided treatment decisions
- Follicular lymphoma and combined therapy approaches
- Venous thromboembolism in patients with cancer
These studies reflect a strong interest in both direct cancer treatment and the prevention of complications that can affect people living with cancer.
Blood Clotting and Vascular Prevention
Another important area of research involves hemic and lymphatic diseases and vascular medicine, including studies of venous thromboembolism, stroke, and other major vascular events. The purpose is to evaluate whether new blood-thinning strategies can better prevent recurrence and reduce serious complications.
- Venous thromboembolism in cancer-associated conditions
- Stroke and recurrent vascular event prevention
- Myocardial infarction and related cardiovascular outcomes
At Centre Hospitalier Du Puy, this research supports safer and more effective prevention strategies for patients at high risk of clotting events.
Infectious Disease and Vaccine Studies
Within the infectiology department, the site is also involved in research on respiratory tract diseases and infection prevention, including work related to pneumococcal infection. These trials are focused on strengthening immune protection and assessing how well vaccination performs in people with increased infection risk.
- Pneumococcal vaccine response in high-risk adults
- Immune response during and after febrile illness
- Prevention of invasive bacterial infection
This area of research helps improve practical vaccination strategies for patients who may be more vulnerable to serious infections.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 10 therapeutic areas and 15 of 65 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 64 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Du Puy
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Open-Label, Randomized Study To Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Combined with Chemotherapy versus Rituximab Combined with Chemotherapy in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-2) | Regeneron Pharmaceuticals Inc. | Phase III | Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 65 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 3 | Unknown | 2024-06-07 | 2026-05-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
